Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: New US Fund of Asia-Based Healthcare VC Seeks USA & Europe Companies in Therapeutics, Medical Device, and Diagnostics Sectors

2 Dec

A new founded US fund of an Asia-based healthcare-focused venture capital firm. The firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to work will entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: European Investment Firm Invests in Novel Therapies in Oncology and Genetic Diseases, Invests Up to $30M Over the Company’s Lifespan

2 Dec

A global investor, headquartered in Europe that was previously focused on oncology has expanded their investments to genetic diseases with its new fund. The firm makes selective investments in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards. The investment size will vary, and it can invest $25-30M over the lifetime of the companies. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Seeks Medical Device & Diagnostics Investments Across the USA, Prefers Companies with Working Prototypes or Strong Proof-of-Concept

2 Dec

A Venture Capital firm based in the USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Invests in Therapeutics & Medical Device Technologies, With Strongest Interest in Therapeutics Solutions Targeting Unmet Medical Need

2 Dec

A Venture Capital firm based in USA manages 5 funds. With the latest fund, the firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6-8 million over the life of the investment. The firm generally looks for companies with lead assets that can reach a high value inflection point in 3-4 years. The firm will consider companies in North America.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics which is the firms primary focus, companies with an asset anywhere from preclinical with positive animal data to Phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Global Services Firm Invests in Software-Based Technologies in the Healthcare Sector, Focusing on Seed to Series A Companies Globally

11 Nov

A venture fund of a global firm that provides software-based services to multiple industries, including healthcare and the life sciences does both venture investing and forms strategic partnerships with companies that are aligned with the firm’s current or future services. As an investor, the firm will generally invest between $200K-3M in seed-series A rounds. For partnerships, the firm is looking for companies looking to scale, potentially working in concert to build clients. The firm will invest and partner globally.

The firm invests in companies developing software-based technologies. Examples of the firm’s services include software for healthcare, such as hospital automation and clinical workflow, as well as virtual care and medical adherence, among others. In the life sciences space, the firm is interested in technologies such as software for connected devices, AI/ML platforms for drug discovery, as well as cell or gene therapies, or decentralized clinical trials, as examples.

The firm is only interested in companies that represent a strategic fit, either for currently offered services, or for complementary services that could expand the firm’s portfolio of services.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based VC With Newly Launched Fund Invests Up to $10M CAD in Therapeutics, Devices, Precision Medicine, and More

11 Nov

A venture capital firm with offices in Canada was founded by a team with a successful track record of identifying, building, and growing life science companies. The firm recently launched a new fund through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Fund Seeks Global Early-Stage Investment Opportunities in Life Sciences with Strong Interests in Platform Technologies

11 Nov

An early stage VC fund formed by alumni of a top tier university currently has $100M under management and focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: